Check-Cap Ltd. logo
Check-Cap Ltd. CHEK
report update icon

Quarterly report 2025-Q4
added 05-12-2026

Check-Cap Ltd. Balance Sheet 2025-2011 | CHEK

Brief overview of Check-Cap Ltd.'s assets and capital

Balance sheet changes are traced across five available annual reports between 2016 and 2023.

Assets advanced +103.5% to $25 million from $12.3 million; annual growth near 10.7% reflects a fast increase in scale.

Liabilities grew more slowly than assets: -29.6% versus +103.5%. Expansion relied more on equity, improving funding quality.

The equity-to-assets ratio is 94.7%, compared with 84.6% five periods ago. The balance sheet has a substantial internal cushion.

Cash accounts for 35.4% of assets versus 94.7% initially. The change indicates the degree of financial flexibility.

The accumulated result is -$144.9 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.

Overall picture

The indicators point to a strong balance sheet position for Check-Cap Ltd.: funding is balanced and liability risks appear controlled.

Annual Balance Sheet Check-Cap Ltd.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- - - -3.13 M - - - - - -11.6 M -9.39 M -1.08 M -4.98 M -4.58 M -

Long Term Debt

- 16 K - 627 K - - - - - - - - - - -

Long Term Debt Current

16 K 120 K - 337 K - 264 K 222 K - - - - - - - -

Total Non Current Liabilities

- 16 K - 721 K 927 K 279 K 393 K 185 K 439 K 521 K 577 K 2.73 M 3.16 M 2.58 M -

Total Current Liabilities

4.05 M 1.81 M 1.33 M 3.41 M 4.04 M 2.98 M 2.8 M 2.22 M 1.56 M 1.37 M 2.07 M - - - -

Total Liabilities

- 1.83 M 1.33 M - - - 3.2 M 2.41 M 2 M 1.89 M 2.65 M 5.56 M 4.18 M 3.37 M -

Retained Earnings

-166 M -170 M -145 M -127 M -108 M -91 M -77.1 M -63.3 M -52.7 M -42.9 M -34.1 M -26.6 M -22.5 M -18.5 M -

Total Assets

7.49 M 377 K 25 M 45.4 M 55.7 M 19.6 M 9.43 M 15.4 M 7.91 M 12.3 M 15.3 M 7.78 M 5.38 M 8.5 M -

Cash and Cash Equivalents

2 K - 8.84 M 4.09 M - 7.7 M 7.68 M 8.57 M 7 M 11.6 M 9.39 M 1.08 M 4.98 M - -

Book Value

7.49 M -1.45 M 23.7 M 45.4 M 55.7 M 19.6 M 6.23 M 13 M 5.9 M 10.4 M 12.6 M 2.23 M 1.19 M 5.13 M -

Total Shareholders Equity

3.44 M -1.45 M 23.7 M 41.3 M 50.7 M 16.4 M 6.23 M 13 M 5.9 M 10.4 M 12.6 M -826 K -528 K - -

All numbers in USD currency

Quarterly Balance Sheet Check-Cap Ltd.

2025-Q4 2025-Q2 2024-Q4 2024-Q2 2023-Q4 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- 16 K 16 K - - - - - - - 795 K - 815 K - 125 K - 121 K - 211 K - 236 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- 16 K 16 K - - - - - - - 927 K - 1 M - 279 K - 298 K - 393 K - 424 K - 185 K - 464 K - 439 K - 570 K - 521 K - 564 K - 577 K - - - 951 K - - - - - - - - - - - - - - -

Total Liabilities

- - 1.83 M - 1.33 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-166 M -165 M -170 M -151 M -145 M -139 M - - - - -108 M - -98.5 M - -91 M - -83.5 M - -77.1 M - -69.8 M - -63.3 M - -57.5 M - -52.7 M - -48.4 M - -42.9 M - -38.8 M - -34.1 M - - - -21.8 M - - - - - - - - - - - - - - -

Total Assets

7.49 M 5.76 M 377 K 18.1 M 25 M 33.7 M - - - - 55.7 M - 32.6 M - 19.6 M - 17.9 M - 9.43 M - 15.9 M - 15.4 M - 20.8 M - 7.91 M - 10.1 M - 12.3 M - 10.7 M - 15.3 M - - - 2.98 M - - - - - - - - - - - - - - -

Cash and Cash Equivalents

2 K 1.16 M - 17.8 M 8.84 M 2.25 M - - - - 26.5 M - 10.1 M - 7.7 M - 8.39 M - 7.68 M - 8.32 M - 8.57 M - 9.96 M - 7 M - 9.15 M - 11.6 M - 8.44 M - 9.39 M - 19.1 M - 1.08 M - - - 4.98 M - - - 4.58 M - - - - - - -

Book Value

7.49 M 5.76 M -1.45 M 18.1 M 23.7 M 33.7 M - - - - 55.7 M - 32.6 M - 19.6 M - 17.9 M - 9.43 M - 15.9 M - 15.4 M - 20.8 M - 7.91 M - 10.1 M - 12.3 M - 10.7 M - 15.3 M - - - 2.98 M - - - - - - - - - - - - - - -

Total Shareholders Equity

3.44 M 3.76 M -1.45 M 17.2 M 23.7 M 30.2 M - - - - 50.7 M - 28.3 M 32.1 M 16.4 M - 15 M 7.66 M 6.23 M - 13.3 M 16.5 M 13 M - 18.5 M 3.34 M 5.9 M - 7.63 M - 10.4 M - 8.72 M - 12.6 M - 17.7 M - -826 K - - - -528 K - - - 2.78 M - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Check-Cap Ltd., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Diagnostics research

Issuer Price % 24h Market Cap Country
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Charles River Laboratories International Charles River Laboratories International
CRL
$ 280.05 0.13 % $ 13.9 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 234.4 0.08 % $ 26 B usaUSA
Biomerica Biomerica
BMRA
$ 1.58 3.18 % $ 3.63 M usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 7.59 3.48 % $ 30.2 M israelIsrael
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Celcuity Celcuity
CELC
$ 92.0 6.24 % $ 4.3 B usaUSA
Co-Diagnostics Co-Diagnostics
CODX
$ 1.4 0.68 % $ 1.86 M usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
DexCom DexCom
DXCM
$ 89.75 0.75 % $ 35 B usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Interpace Biosciences Interpace Biosciences
IDXG
$ 1.66 0.6 % $ 7.34 M usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
- - $ 2.69 B usaUSA
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 163.15 0.19 % $ 12.8 B irlandaIrlanda
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 236.66 0.28 % $ 40.7 B usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
T2 Biosystems T2 Biosystems
TTOO
- -39.35 % $ 313 K usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 3.18 0.93 % $ 103 K usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
Meridian Bioscience Meridian Bioscience
VIVO
- - $ 1.49 B usaUSA
ENDRA Life Sciences ENDRA Life Sciences
NDRA
$ 4.47 1.36 % $ 3.52 M usaUSA
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
Natera Natera
NTRA
$ 309.93 1.04 % $ 42.4 B usaUSA
Myriad Genetics Myriad Genetics
MYGN
$ 3.03 0.62 % $ 281 M usaUSA
NeoGenomics NeoGenomics
NEO
$ 15.94 0.24 % $ 2.04 B usaUSA
National Research Corporation National Research Corporation
NRC
$ 21.19 0.84 % $ 474 M usaUSA
Surmodics Surmodics
SRDX
- - $ 608 M usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 27.29 0.51 % $ 25.9 B niderlandNiderland
Quidel Corporation Quidel Corporation
QDEL
$ 14.3 1.75 % $ 602 M usaUSA